Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANGOKIDS: Vabomere in Pediatric Subjects With Serious Bacterial Infections
NCT02687906Phase 1Completed
- Sponsor
- Rempex Pharmaceuticals
- Start
- Jul 2016
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vaborbactam in bacterial infection, sponsored by Rempex Pharmaceuticals. Primary endpoints: Area Under the Curve from Time Zero to Infinity at 6 hours, Maximum Plasma Concentration at 6 hours and 9 more. Started Jul 2016; status: completed.
02
Drugs
vaborbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02687906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687906.